33 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Compared to Estimates, M&T Bank Corporation (MTB) Q4 Earnings: A Look at Key Metrics https://www.zacks.com/stock/news/2212081/compared-to-estimates-m-t-bank-corporation-mtb-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2212081 Jan 18, 2024 - While the top- and bottom-line numbers for M&T Bank Corporation (MTB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Macy's (M) Stock Dips While Market Gains: Key Facts https://www.zacks.com/stock/news/2209805/macy-s-m-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2209805 Jan 12, 2024 - Macy's (M) concluded the recent trading session at $18.54, signifying a -0.43% move from its prior day's close.
Exploring Analyst Estimates for M&T Bank Corporation (MTB) Q4 Earnings, Beyond Revenue and EPS https://www.zacks.com/stock/news/2209609/exploring-analyst-estimates-for-m-t-bank-corporation-mtb-q4-earnings-beyond-revenue-and-eps?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2209609 Jan 12, 2024 - Beyond analysts' top -and-bottom-line estimates for M&T Bank Corporation (MTB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
M&T Bank Corporation (MTB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release https://www.zacks.com/stock/news/2208935/m-t-bank-corporation-mtb-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2208935 Jan 11, 2024 - M&T Bank Corporation (MTB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for M&T Bank (MTB) This Earnings Season? https://www.zacks.com/stock/news/2208293/what-s-in-store-for-m-t-bank-mtb-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2208293 Jan 10, 2024 - Increasing funding costs are likely to have hurt M&T Bank's (MTB) Q4 NII growth. Also, declining non-interest income is likely to have affected the company's top-line growth.
Barron’s cites cancer and weight loss plays for biotech M&A https://seekingalpha.com/news/4053547-barrons-cites-cancer-weight-loss-plays-biotech-ma?source=feed_sector_healthcare Jan 09, 2024 - On the back of recent deals involving big pharma, Barron’s issued positive remarks on a possible acceleration of biotech M&A activity on Tuesday. Read more here.
Why M&T Bank Corporation (MTB) is Poised to Beat Earnings Estimates Again https://www.zacks.com/stock/news/2207137/why-m-t-bank-corporation-mtb-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2207137 Jan 08, 2024 - M&T Bank Corporation (MTB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Goldman (GS) Tops in M&A Advisory Despite Dealmaking Lull https://www.zacks.com/stock/news/2205804/goldman-gs-tops-in-m-a-advisory-despite-dealmaking-lull?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2205804 Jan 04, 2024 - Goldman (GS) advises on 235 announced M&As in 2023, with an aggregate value of more than $671 billion. With this, it has a 31% market share of the global merger advisory.
What's in store for biotech M&A and IPOs in 2024? https://seekingalpha.com/news/4051438-whats-in-store-for-biotech-mergers-and-ipos-in-2024?source=feed_sector_healthcare Jan 01, 2024 - Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.
Needham says Cytokinetics' appeal as M&A target enhanced by HCM data https://seekingalpha.com/news/4051040-needham-says-cytokinetics-appeal-as-ma-target-enhanced-by-hcm-data?source=feed_sector_healthcare Dec 28, 2023 - Cytokinetics' (CYTK) attractiveness as a takeover target has been enhanced by positive data for its hypertrophic cardiomyopathy drug aficamten, according to Needham.

Pages: 1234

<<<Page 3